Our conclusion is that there is more to come. Nevertheless, we like this move as it improves the divisions in areas where there are weaknesses: medtech and biosimilars. The latter might be somewhat surprising bearing in mind the company’s high ambitions. The management has indicated that this is the first step but we are missing the big picture. The company has announced a meet the management focussing on Kabi although note that there were many such events promised but not delivered in 2021.